Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: The existing evidence regarding the impact of tamoxifen on lipoprotein(a) and apolipoproteins remains inconsistent. Therefore, this updated meta-analysis of randomized controlled trials (RCTs) aims to enhance the quality of evidence concerning the effects of tamoxifen on these lipid parameters.
Methods: Eligible RCTs published up to October 2024 were meticulously selected through a comprehensive search. A meta-analysis was then performed using a random-effects model, and results were presented as the weighted mean difference (WMD) with a 95% confidence interval (CI).
Results: Findings from the random-effects model revealed an increase in ApoA-I (WMD: 15.22 mg/dL, 95% CI: 6.43-24.01, P = 0.001), alongside decreases in ApoB (WMD: -9.33 mg/dL, 95% CI: -15.46 to -3.19, P = 0.003) and lipoprotein(a) (WMD: -3.35 mg/dL, 95% CI: -5.78 to -0.91, P = 0.007) levels following tamoxifen treatment in women. Subgroup analyses indicated a more significant reduction in lipoprotein(a) levels in RCTs with a duration of ≤24 weeks (WMD: -3.65 mg/dL) and in studies using tamoxifen doses of ≥20 mg/day (WMD: -4.53 mg/dL).
Conclusion: This meta-analysis provides evidence that tamoxifen leads to a decrease in lipoprotein(a) levels, along with reductions in ApoB and increases in ApoA-I among women.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12020-024-04128-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipoprotein(a) at a "Tipping Point": case to move to universal screening.
Am J Prev Cardiol
September 2025
Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.
Elevated lipoprotein(a) [Lp(a)] is well established as a common risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) levels are >90 % genetically determined. However, Lp(a) remains very underrecognized as a cardiovascular risk factor with low rates of testing.
View Article and Find Full Text PDFElevated Lipoprotein(a) Levels and Massive Ruptured Root and Ascending Aortic Aneurysm.
JACC Case Rep
September 2025
Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Cardiac Surgery, St Michael's Hospital of Unity Health Toronto, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada; Department of Surgery, University of Toronto, Toronto, Ontario, Canada; Department of P
Background: Rupture of a root and ascending aortic aneurysm is a rare, life-threatening condition requiring prompt recognition and surgical intervention. Elevated lipoprotein(a) levels have been implicated in vascular pathology but are less studied in thoracic aneurysms.
Case Summary: A 61-year-old man who presented with severe dyspnea and chest tightness was found to have a 7.
The challenge of secondary cardiovascular prevention in very high Lipoprotein (a) level: a case report.
Eur Heart J Case Rep
September 2025
Cardio-Thoracic-Vascular Department, Cardiology Unit, Azienda Ospedaliera Carlo Poma, ASST Mantova, Str. Lago Paiolo 10, Mantova 46100, Italy.
Background: While advances in technology and procedural techniques have significantly improved outcomes post-PCI, two pharmacological strategies have gained particular attention for their effectiveness in reducing long-term cardiovascular (CV) risk: anti-platelet therapies and lipid-lowering therapies (LLT). The 10-year recurrence risk for major CV events remains as high as 10-30%, due to various pathophysiological pathways collectively known as residual risk (RR), even with optimal CV risk factor management after acute coronary syndrome (ACS). RR includes factors such as elevated lipoprotein(a) [Lp(a)], triglycerides, pro-thrombotic states, hyperglycemia, and persistent subclinical arterial inflammation.
View Article and Find Full Text PDFFuelling aortic stenosis: the integral role of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3-mediated glycolysis in Lp(a)-induced valve inflammation.
Eur Heart J Open
July 2025
Amsterdam UMC Location University of Amsterdam, Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ Amsterdam, Netherlands.
Aims: Calcific aortic valve disease is the most common valvular heart disease characterized by an inflammatory response in the leaflets followed by fibro-calcific remodelling of valvular interstitial cells (VICs). Lipoprotein(a) [Lp(a)] is a well-recognized risk factor for CAVD, however the role of metabolism in driving Lp(a)-induced inflammation remains largely elusive. Therefore, we aim to investigate the role of Lp(a) in driving inflammatory and metabolic changes in VICs and examine how alterations in cellular metabolism can alter their inflammatory phenotype.
View Article and Find Full Text PDFOne-Year Outcomes in PAD Patients with Elevated Lipoprotein(a): A Propensity-Matched Analysis.
Am J Cardiol
September 2025
CAMC Department of Cardiology, Charleston Area Medical Center, 3100 McCorkle Ave SE, Charleston, WV, 25302.
Background: Lipoprotein(a) [Lp(a)] is a genetically determined, proatherogenic lipoprotein linked to increased cardiovascular risk. Although elevated Lp(a) levels have been implicated in peripheral artery disease (PAD) development, their prognostic significance in patients with established PAD remains unclear.
Objectives: To evaluate whether elevated Lp(a) independently predicts short-term cardiovascular and limb outcomes in patients with established PAD.